GlassScriptPhysician profile
Roberto Pili
NPI 1669419867
$7,219.35
in general payments reported to CMS, 2019-2025
25 companies · $479 in 2025
The $479 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $4,737 · 2021: $23.53 · 2022: $187 · 2023: $162 · 2024: $230 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.04 |
| Education | $150.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clinigen, INC. | $4,724.50 | 2020 | |
| Pfizer INC. | $1,587.35 | 2019-2025 | |
| Galvanize Therapeutics, INC | $179.86 | 2025 | Aliya System |
| Astellas Pharma US INC | $139.32 | 2022-2025 | Xtandi |
| Novartis Pharmaceuticals Corporation | $120.78 | 2022-2025 | |
| Exact Sciences Corporation | $97.40 | 2024 | Cologuard Collection Kit |
| Celgene Corporation | $79.52 | 2025 | Reblozyl |
| Janssen Biotech, INC. | $67.64 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Daiichi Sankyo INC. | $32.92 | 2022 | |
| Adaptive Biotechnologies Corporation | $24.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.45 | 2023 | Opdivo |
| Exelixis INC. | $17.33 | 2024 | Cabometyx |
| Sandoz INC. | $17.32 | 2022 | |
| Amgen INC. | $16.91 | 2023 | Nplate, Vectibix, Xgeva |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $15.20 | 2024 | |
| Aveo Pharmaceuticals, INC. | $15.00 | 2024 | |
| Emd Serono, INC. | $14.97 | 2023 | Bavencio |
| Merck Sharp & Dohme LLC | $10.87 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Pili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.